MLchartDataset catalogue

Brukinsa

Term · Oncology and biomedicine · MLC-T-ONC-001277

A drug used alone or with another drug to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain types of non-Hodgkin lymphoma, including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia. It is also being studied in the treatment of other types of cancer. Brukinsa blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called zanubrutinib.

Table 1. Record
IdentifierMLC-T-ONC-001277
FieldOncology and biomedicine
Synonymszanubrutinib
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-001277",
  "term": "Brukinsa",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with another drug to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain types of non-Hodgkin lymphoma, including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia. It is also being studied in the treatment of other types of cancer. Brukinsa blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called zanubrutinib.",
  "synonyms": [
    "zanubrutinib"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/brukinsa/"
}

Record 3,902 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.